But, like Merck two weeks ago, GSK has failed to hit overall survival.
ApexOnco Front Page
Recent articles
Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
Reports of Arc-10's failure are greatly exaggerated, the company argues.
The company abandons TNG908, but is still all in on the troubled target.
An ASH abstract reveals no delayed neurotoxicity, but three deaths, with anito-cel.
Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.
October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.
After beating "historical" Xtandi masofaniten fails to beat actual Xtandi.
